Search
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalDeveloped by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153] … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.
Folitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).
LGD-1550
go.drugbank.com/drugs/DB05785ExperimentalLGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.
Certoparin
go.drugbank.com/drugs/DB09261ApprovedCertoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
Olacaftor
go.drugbank.com/drugs/DB16262InvestigationalOlacaftor is under investigation in clinical trial NCT02951182 (A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis).
Crenolanib
go.drugbank.com/drugs/DB11832InvestigationalCrenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.
Wilson's Disease
go.drugbank.com/conditions/DBCOND0032702Synonyms: Westphal-Strumpell form of Wilson's diseaseAN0128
go.drugbank.com/drugs/DB05054InvestigationalAN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis. … Of particular importance is P. acnes and its causal role in acne vulgaris. The rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.
Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalIt is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].
G4544
go.drugbank.com/drugs/DB05244ExperimentalG4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). … It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabolically active.